Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Large B-Cell, Diffuse 25Multiple Myeloma 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Mantle-Cell 17Lymphoma, Non-Hodgkin 14Lymphoma, T-Cell 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, B-Cell 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Mycosis Fungoides 8Leukemia, Biphenotypic, Acute 8Lymphoma, Large-Cell, Anaplastic 7Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Leukemia, Myelomonocytic, Chronic 5Histiocytosis, Langerhans-Cell 5Glioma 5Wilms Tumor 4Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Rhabdoid Tumor 4Medulloblastoma 4

Interventions

talimogene laherparepvec 1Specimen Handling 1Nivolumab 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Muir-Torre Syndrome × Biopsy × Lymphoid × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡